Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy☆
Section snippets
Design
The protocol was reviewed and approved by our institutional Human Subjects Committee. The study protocol and inclusion and exclusion criteria have been previously reported.21 No subjects had evidence of vascular disease.
In brief, 3 groups of subjects were initially recruited: (1) type 2 diabetes, defined for the purposes of this study as fasting plasma glucose (FPG) greater than 6.9 mmol/L; (2) obese controls with FPG less than 6.1 mmol/L matched to the diabetic subjects for BMI, age, and
Results
Table 1 lists characteristics of the study participants. Diabetic subjects had been advised in a weight maintenance diet and body weights were stable at the time of GCRC admission (92.3 ± 3.1 kg at the initial GCRC admission and 92.4 ± 3.1 when determined at SV2, 2 to 3 weeks before admission).
As shown in Fig 1, adiponectin concentrations were highest in non-obese controls and progressively decreased when compared to obese subjects, IFG/mild diabetes, and type 2 diabetes. CRP concentrations
Discussion
Previous studies show that adiponectin is reduced,9, 10 while CRP is elevated2, 13, 14, 15 in subjects with features of the metabolic syndrome. While confirming these general concepts, our current work examines both of these parameters concurrently over a spectrum of age-matched subjects with varying glucose tolerance and adiposity from normal, through IFG, to type 2 diabetes. We also report the effect of 2 forms of monotherapy on adiponectin and CRP in subjects off drug treatment at the onset
References (40)
- et al.
Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes
FEBS Lett
(1988) - et al.
ACRP30/adiponectinAn adipokine regulating glucose and lipid metabolism
Trends Endocrinol Metab
(2002) - et al.
Adiponectin as a novel determinant of bone mineral density and visceral fat
Bone
(2003) - et al.
C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue?
Arterioscler Thromb Vasc Biol
(1999) - et al.
Leptin and the cardiovascular system
Recent Prog Horm Res
(2004) - et al.
Leptin signaling in the central nervous system and the periphery
Recent Prog Horm Res
(2004) - et al.
Hypoadiponectinemia is closely linked to endothelial dysfunction in man
J Clin Endocrino Metab
(2003) - et al.
Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population
Clin Sci
(2002) - et al.
Markers of inflamation and cardiovascular disease
Circulation
(2003) - et al.
The role of the novel adipocyte-derived hormone adiponectin in human disease
Eur J Endocrinol
(2003)
AdiponectinMore than just another fat cell hormone?
Diabetes Care
Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice
Proc Natl Acad Sci USA
Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase
Nat Med
Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women
Arterioscler Thromb Vasc Biol
Association between C-reactive protein and features of the metabolic syndromeA population-based study
Diabetes Care
Body mass index, diabetes, and C-reactive protein among U.S. adults
Diabetes Care
Markers of inflammation and coronary artery disease
Mel Sci Monitor
Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes
J Clin Invest
The influence of salicylates on hyperglycemia
Diabetes
Aspirin causes tissue insensitivity to insulin in normal man
J Clin Endocrinol Metabol
Cited by (60)
The key role of inflammation in the pathogenesis and management of obesity and CVD
2023, Metabolism: Clinical and ExperimentalCOVID-19 and sulfonylureas: A reminder of the pleiotropic actions of an old class of drugs just before their swansong
2022, Metabolism: Clinical and ExperimentalDiabetes and calcification: The potential role of anti-diabetic drugs on vascular calcification regression
2020, Pharmacological ResearchRelation of antioxidant capacity of diet and markers of oxidative status with C-reactive protein and adipocytokines: a prospective study
2017, Metabolism: Clinical and ExperimentalCitation Excerpt :Plasma sensitive CRP (hs-CRP) correlates with obesity and obesity-related disorders, including insulin resistance and type 2 diabetes [5]. Adipose tissue synthesizes and releases many inflammatory mediators into the systemic circulation termed adipocytokines, and include leptin, adiponectin, plasminogen activator inhibitor-1 (PAI-1) and resistin, all of which can initiate the development of chronic inflammation and may directly contribute to metabolic and vascular diseases [6–15]. An imbalance between plasma oxidants-antioxidants (oxidative stress) as well as dietary antioxidants have been suggested to play a role in systemic low-grade chronic inflammation [16].
Diabetes medications: Impact on inflammation and wound healing
2016, Journal of Diabetes and its ComplicationsCitation Excerpt :The switch was associated with increased adiponectin and decreased plasma TNF-α, IL-6, and hs-CRP levels compared to patients maintained on glyburide or insulin treated patients (Koshiba, Nomura, Nakaya, & Ito, 2006). Another study on treatment naive type 2 diabetes patients comparing glyburide vs. metformin monotherapy titrated for glycemic control to dosages up to 20 mg/day for glyburide or 2,550 mg/day for metformin indicated that only glyburide was able to induce a reduction in CRP levels within a 3 month time-frame (Putz, Goldner, Bar, Haynes, & Sivitz, 2004). Together, these studies point to the systemic anti-inflammatory potential of sulfonylureas in patients with diabetes.
Coffee Consumption and Adiponectin: An Overview of Epidemiological Studies
2015, Coffee in Health and Disease Prevention
- ☆
Supported by The Department of Veterans Affairs Office of Research and Development, the Juvenile Diabetes Foundation International, Grant No. DK25295 from the National Institutes of Health, and by Grant No. M01-RR00059 from the National Center for Research Resources, General Clinical Research Centers Program, National Institutes of Health.